Barclays
AMRI

Barclays’s Albany Molecular Research Inc AMRI Stock Holding History

Barclays’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66,800
Closed -$1.45M – 7268
2017
Q2 		$1.45M Buy
66,800
+63,600
+1,988% +$1.15M ﹤0.01% 2543
2017
Q1 		$45K Sell
3,200
-4,000
-56% -$65.5K ﹤0.01% 5403
2016
Q4 		$135K Buy
7,200
+2,700
+60% +$45.9K ﹤0.01% 4535
2016
Q3 		$74K Sell
4,500
-7,700
-63% -$114K ﹤0.01% 4729
2016
Q2 		$164K Hold
12,200
– – ﹤0.01% 4074
2016
Q1 		$183K Buy
12,200
+9,200
+307% +$144K ﹤0.01% 3905
2015
Q4 		$57K Sell
3,000
-1,600
-35% -$30.4K ﹤0.01% 4719
2015
Q3 		$78K Buy
4,600
+2,200
+92% +$44.8K ﹤0.01% 4776
2015
Q2 		$48K Buy
2,400
+500
+26% +$9.65K ﹤0.01% 5179
2015
Q1 		$32K Buy
1,900
+100
+6% +$1.7K ﹤0.01% 5590
2014
Q4 		$29K Buy
1,800
+600
+50% +$11K ﹤0.01% 6099
2014
Q3 		$26K Sell
1,200
-2,500
-68% -$51.2K ﹤0.01% 6339
2014
Q2 		$74K Buy
+3,700
New +$62.7K ﹤0.01% 5662

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Barclays's AMRI Position: Q3 2017 in Review

Barclays sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 122,925 shares — an estimated $2.67M sold.

Barclays first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $2.67M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Barclays reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Barclays sold 122,925 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.67M.
  • Barclays first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
  • Barclays's Albany Molecular Research Inc position peaked at $2.67M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.